Tuesday, December 9, 2025

MindMed Activist Investor Moves To Take Control Of Board

MindMed (NASDAQ: MNMD) has seen its activist investor file a preliminary proxy statement for its proposed set of directors after the firm indicated last year it intended to work to take control of the company. The activist investor, FCM MM Holdings, is ran by a former co-founder of MindMed, Dr Scott Freeman.

Describing itself as “one of MindMed’s largest investors,” the firm has just a 3.5% stake in the company, yet is attempting to exert control. FCM proposed a total of four directors for the firms board, including Dr Scott Freeman, co-founder of MindMed and former Chief Medical Officer, Dr Farzin Farzaneh, a professor of molecular medicine at King’s College London, Vivek Jain, a venture capitalist, and Alexander Wodka, a former partner at Crowe.

In announcing that the filing has been made, FCM highlighted that MindMed has seen its shares decline 89% over the past year, despite its peer group falling on average 62%.

The firm also addressed recent comments by MindMed wherein the company referred to FCM as not having paid a “control premium,” which FCM claims is “simply mendacious,” given the fact that they are not seeking a buy out (they just want control instead). FCM claims that they are simply looking to repair operational challenges and restore shareholder value.

“Since 2021, I have been proactively engaging the Board about the delays in the MM-110 and MM-120 programs. Unfortunately, these entreaties were ignored, and subsequently, management botched the MM-110 program while the MM-120 program is over a year behind schedule due to a myriad of operational failures. As a result, I believe the only path forward for MindMed is an immediate reconstitution of the Board,” commented Freeman.

MindMed last traded at $3.81 on the Nasdaq.


Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Why Canada Has So Few Projects That Can Be Built Before 2030 | Dan Wilton – First Mining

Guanajuato Silver: Q3 Results Overshadowed By Silver Ripping

I Went to See the Highest Grade Silver on Earth | Nord Precious Metals

Recommended

Emerita Resources Awards Contract For Pre-Feasibility Study On Iberian Belt West Project

Selkirk Copper Appoints Two Members Of Selkirk First Nation To Leadership Team

Related News

Canaccord Raises Mind Medicine’s Price Target To $2.00 Following Financing

This morning, Canaccord Genuity raised its 12-month price target on Mind Medicine (NEO: MMED) from...

Monday, November 2, 2020, 10:45:02 AM

Mind Medicine: Canaccord Genuity Initiates Coverage With C$1.75 Price Target

Yesterday, Canaccord initiated coverage on Mind Medicine (NEO: MMED) with a Speculative Buy rating and...

Wednesday, September 16, 2020, 04:15:00 PM

MindMed Declares Q2 2021 Financials: US$193.9 Million Total Assets, US$35.6 Million Net Loss

Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, announced Thursday night its interim...

Friday, August 13, 2021, 09:08:00 AM

MindMed To Begin Trading On The Nasdaq April 27

MindMed (NEO: MMED) is moving up to the big leagues. The psychedelics company this morning...

Friday, April 23, 2021, 09:11:58 AM

Mind Medicine Prices $30 Million Offering At 30% Discount To Market

Mind Medicine (NEO: MMED) has elected to destroy shareholder value in a major way this...

Wednesday, September 28, 2022, 09:28:04 AM